Atonco, an innovative company specializing in the development of next-generation radiopharmaceuticals based on astatine-211, today announced the promotion of Alexandra Paillard to Chief Operating Officer, effective October 1, 2025.
Following this appointment, Alexandra Paillard will also take on the role of Deputy Managing Director, overseeing all operations related to the technical and clinical development of Atonco’s licensed radiopharmaceuticals.
With a doctorate in pharmacy and a PhD in pharmaceutics, Alexandra Paillard has solid experience in managing complex projects in biotechnology and pharmaceutical development. Her mission will be to strengthen and accelerate Atonco’s operational strategy around its core business: astatine-211-based radiopharmaceuticals, notably ATO-101™, developed as part of a new-generation alpha-immunotherapy approach.
This appointment marks an important step in the structuring of Atonco and confirms the company’s ambition to become a global leader in the field of targeted alpha radiotherapy.
“Alexandra Paillard’s promotion reflects our confidence in her ability to lead our operations into a new phase of growth and industrial transposition. Her leadership will be instrumental in realizing the unique therapeutic potential of our astatine-211-based radiopharmaceuticals,“ said Sylvain Fanier, President of Atonco.
Alexandra Paillard said: ” It is an honor to take over the management of Atonco’s operations at such a strategic moment in its development. Astatine-211 represents a unique opportunity to transform the care of many cancer patients, and I am fully committed to working with our teams and partners to bring our portfolio of radiopharmaceuticals, including ATO-101™, to the next clinical and industrial stages.”
About Atonco
Atonco is an innovative biopharmaceutical company dedicated to the development of next-generation radiopharmaceuticals based on astatine-211, a promising alpha emitter for targeted cancer therapies. Its lead program, ATO-101™, is being developed under an exclusive license for girentuximab from Telix Pharmaceuticals and is part of a new high-precision therapeutic approach to cancers that are resistant to conventional treatments.